Benitec Biopharma Inc. (BNTC) Earnings History
Net Loss13 years of earnings data (2013–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Benitec Biopharma Inc. (BNTC) Earnings Overview
As of June 23, 2026, Benitec Biopharma Inc. (BNTC) reported trailing twelve-month net income of -$49M, reflecting +60.8% year-over-year growth. The company earned $-0.99 per diluted share over the past four quarters.
Looking at the long-term picture, BNTC's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2019.
Benitec Biopharma Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KRYS ($225M net income, 52.6% margin), RCKT (-$209M net income), QURE (-$209M net income, -1236.0% margin), BNTC has comparable earnings metrics. Compare BNTC vs KRYS →
BNTC Earnings vs Peers
Earnings metrics vs comparable public companies
BNTC Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$38M | -74.3% | -$42M | $-1.05 | - | - |
| 2024 | -$22M | -11.2% | -$22M | $-2.68 | - | - |
| 2023 | -$20M | -7.4% | -$19M | $-14.12 | -26082.7% | -25441.3% |
| 2022 | -$18M | -31.2% | -$18M | $-19.31 | -24942.5% | -24457.5% |
| 2021 | -$14M | -67.8% | -$14M | $-27.27 | -23528.8% | -23044.1% |
| 2020 | -$8M | -553.7% | -$8M | $-69.09 | -8529.9% | -8537.1% |
| 2019 | $2M | +129.0% | $2M | $28.45 | 22.6% | 22.4% |
| 2018 | -$6M | -88.0% | -$6M | $-103.61 | -3079.4% | -3143.9% |
| 2017 | -$3M | +75.8% | -$12M | $-63.55 | -1708.7% | -6222.9% |
| 2016 | -$14M | -105.7% | -$19M | $-331.56 | -5340.1% | -7204.2% |
| 2015 | -$7M | +34.1% | -$10M | $-194.88 | -1064.7% | -1607.6% |
| 2014 | -$10M | -71.4% | -$14M | $-305.54 | -1064.7% | -1414.9% |
| 2013 | -$6M | - | -$8M | $-724.71 | -1177.1% | -1494.9% |
Download Data
Export BNTC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BNTC — Frequently Asked Questions
Quick answers to the most common questions about buying BNTC stock.
What is BNTC earnings per share (EPS)?
BNTC trailing twelve-month (TTM) diluted EPS is $-0.99, reflecting +60.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.
What is Benitec Biopharma Inc.'s net income?
Benitec Biopharma Inc. (BNTC) trailing twelve-month net income is $-49M as of 2025. Earnings grew +60.8% year-over-year.
Is BNTC profitable?
BNTC is not currently profitable on a TTM basis, reporting a net loss of $-49M. Net margin is N/A. Investors should monitor for a return to profitability.
What is BNTC's earnings growth rate?
BNTC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.
What are BNTC's profit margins?
Benitec Biopharma Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -52.5%.
Is BNTC growing earnings?
Yes, BNTC earnings are accelerating — EPS growth of +60.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-49M. Earnings momentum is strengthening.
What was BNTC's best earnings year?
Benitec Biopharma Inc.'s highest annual net income on record is $2M, achieved in fiscal year 2019. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.
What were BNTC's earnings last quarter?
BNTC's most recent reported quarter was Q3 2026. Net income was $-12M with diluted EPS of $-0.24. For a full breakdown of all quarters, see the quarterly earnings table on this page.